|
DAPC
Diabetic Atherosclerosis Prevention by Cilostazol
Ongoing trial
 |
Author(s) |
Yamasaki Y, Kim Y-S, Kawamori R |
 |
Title(s) |
Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study) |
|
Reference(s) |
Cardiovasc Diabetol 2006;5:16–9 |
|
Disease |
Atherosclerosis |
|
Purpose |
To determine the efficacy and safety of antiplatelet therapy in the prevention of atherosclerosis in patients with diabetes mellitus |
|
Study design |
Randomised, parallel-group |
|
Follow-up |
Aim 2 years |
|
Patients |
Aim 408 patients, aged 40–85 years, with type 2 diabetes and clinical findings suggestive of arteriosclerosis obliterans |
|
Treatment regimen |
Cilostazol, 100–200 mg/day, or ASA, 81–100 mg/day |
|
Results |
Not yet available |
|
|
|
